# A Study of APG-3288 in Relapsed/Refractory Blood Cancers

> **NCT07424833** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 180 (estimated)

## Conditions studied

- Relapsed/Refractory Hematological Malignancies
- Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL
- Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)
- Relapsed/Refractory Mantle Cell Lymphoma (MCL)
- Relapsed/Refractory Waldenström Macroglobulinemia (WM)
- Relapsed/Refractory Marginal Zone Lymphoma (MZL)
- Relapsed/Refractory Follicular Lymphoma (FL)

## Interventions

- **DRUG:** APG-3288

## Key facts

- **NCT ID:** NCT07424833
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2029-12
- **Final completion:** 2031-12
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07424833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07424833, "A Study of APG-3288 in Relapsed/Refractory Blood Cancers". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07424833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*